Sun Pharma Advanced Research Company Limited (SPARC) announced the approval of its Unaudited Standalone and Consolidated Financial Results for the third quarter and nine months ended December 31, 2025. The results reflect an exceptional item of ₹1,236 Lakhs recognized due to the implementation of the Government of India’s New Labour Codes effective November 21, 2025. The board meeting concluded on February 9, 2026.
Board Approval of Q3 FY2026 Financials
The Board of Directors of Sun Pharma Advanced Research Company Limited (SPARC) convened on February 09, 2026, and formally approved the Unaudited Standalone and Consolidated Financial Results for the quarter and nine months ending December 31, 2025. The Board meeting commenced at 11:15 AM (IST) and concluded at 01:15 PM (IST).
Standalone Financial Highlights (Q3 Ended Dec 31, 2025)
In the standalone results, the Profit/(Loss) before tax for the quarter was (₹8,057) Lakhs, compared to (₹7,971) Lakhs in the corresponding quarter of the previous year (Q3 FY2025). For the nine months ended December 31, 2025, the consolidated Profit/(Loss) before tax stood at (₹20,857) Lakhs.
Consolidated Financial Performance
On a consolidated basis for the quarter ended December 31, 2025, the Total Income was ₹845 Lakhs. The resulting Profit/(Loss) for the period was (₹8,042) Lakhs. For the nine months ended the same date, the consolidated Total comprehensive profit/(loss) for the period attributable to owners of the company was (₹20,692) Lakhs.
Impact of New Labour Codes
A significant event impacting the current period is the recognition of an incremental cost of ₹1,236 Lakhs during the quarter ended December 31, 2025. This cost stems from the assessment of the implications arising from the Government of India’s consolidation of 29 labour legislations into the New Labour Codes, effective November 21, 2025. This amount has been recognized and disclosed specifically as an Exceptional Item in both standalone and consolidated results.
Business Updates
The Company noted that on February 03, 2026, the United States Food and Drug Administrator granted a Rare Pediatric Disease Priority Review Voucher (PRV) associated with the approval of Sezaby®. SPARC operates within a single reportable segment: ‘Pharmaceutical Research and Development’.
Auditor’s Conclusion
SRBC & CO LLP issued an Independent Auditor’s Review Report on both standalone and consolidated results. Based on their review, nothing has come to their attention that causes them to believe that the statements, prepared under the relevant Indian Accounting Standards (‘Ind AS’), are materially misstated or fail to disclose required information as per the Listing Regulations.
Source: BSE
